Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
253 stopped studies mapped to Malignant Endocrine Neoplasm and descendants · 91% state a reason
Over the 253 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01803269 | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating… | Phase 2 | terminated | Mar 4, 2013 | University of Chicago | Due to lack of activity and slow accrual | Enrollment / accrual |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated…(CARACTER) | N/A | terminated | Mar 13, 2013 | Amphia Hospital | bad taste of Caphosol - early stop of intake by patients | Other (stated, no rule matched) |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | Phase 1 | terminated | Apr 26, 2010 | University of Maryland, Baltimore | Toxicity was not felt to be acceptable for further development. | Safety / toxicity |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients… | Phase 1 | terminated | Jun 30, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT03168594 | Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With… | Phase 2 | terminated | May 30, 2017 | Peking University | The enrollment was terminated early because the premature analysis found similar response in the… | Enrollment / accrual |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | — | terminated | Apr 10, 2012 | Addario Lung Cancer Medical Institute | interim assessment by sponsor | Other (stated, no rule matched) |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | Phase 1 | terminated | Jul 20, 2010 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | Phase 2 | withdrawn | Aug 1, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or… | Phase 1 | terminated | Oct 29, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | Budget/Funding | Funding |
| NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | Phase 1 | terminated | Jan 13, 2014 | GlaxoSmithKline | The risk benefit in relapsed refractory SCLC does not favor continuation of the study | Other (stated, no rule matched) |
| NCT01974284 | Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | N/A | terminated | Nov 1, 2013 | Yale University | Lack of patient enrollment | Enrollment / accrual |
| NCT00537511 | A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047… | Phase 1 / Phase 2 | terminated | Oct 1, 2007 | Celgene | This study was terminated for administrative reasons. | Other (stated, no rule matched) |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced… | Phase 1 / Phase 2 | withdrawn | Jan 8, 2014 | University of Maryland, Baltimore | PI has left the study institution. | Other (stated, no rule matched) |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02937402 | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune… | N/A | terminated | Oct 18, 2016 | Vanderbilt-Ingram Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given… | Phase 2 | terminated | Apr 9, 2014 | Clovis Oncology, Inc. | not stated | Not stated |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With… | Phase 1 | terminated | Feb 20, 2015 | Millennium Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT02720484 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | Phase 2 | terminated | Mar 28, 2016 | Northwestern University | Study did not meet first stage requirements of interim analysis | Efficacy / futility |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 4, 2015 | Zhejiang Provincial People's Hospital | No recruitment. | Enrollment / accrual |
| NCT00969306 | Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients(Chloroquine IV) | Phase 1 | terminated | Sep 1, 2009 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Nov 6, 2012 | Eli Lilly and Company | Change in clinical strategy. | Sponsor / business decision |
| NCT03334487 | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment… | Phase 3 | withdrawn | Nov 7, 2017 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome… | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual,primary endpoint reached \& investigator left NIH. | Investigator |
| NCT03366675 | AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] | Phase 2 | terminated | Dec 8, 2017 | Samsung Medical Center | Early detection of the purpose of the study. | Other (stated, no rule matched) |
| NCT00702962 | Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive… | Phase 1 / Phase 2 | terminated | Jun 20, 2008 | Milton S. Hershey Medical Center | Poor accrual | Enrollment / accrual |
| NCT02500914 | SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma | Phase 1 | terminated | Jul 17, 2015 | Stemcentrx | Strategic Considerations | Sponsor / business decision |
| NCT02688907 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer… | Phase 2 | terminated | Feb 23, 2016 | Samsung Medical Center | change regimen | Other (stated, no rule matched) |
| NCT03106155 | Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring…([SUKSES-D]) | Phase 2 | terminated | Apr 10, 2017 | Samsung Medical Center | Decision of IP support organization | Other (stated, no rule matched) |
| NCT02011087 | Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With… | N/A | terminated | Dec 13, 2013 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01325753 | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or… | N/A | withdrawn | Mar 30, 2011 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Phase 1 / Phase 2 | terminated | Jan 6, 2015 | Western Regional Medical Center | PI not longer at site. | Other (stated, no rule matched) |
| NCT02748889 | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small… | Phase 1 / Phase 2 | terminated | Apr 22, 2016 | Giuseppe Giaccone | Difficulties with recruitment | Enrollment / accrual |
| NCT02161419 | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer(CONCEPT-SCLC) | Phase 2 | terminated | Jun 11, 2014 | Bayer | not stated | Not stated |
| NCT02250404 | Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung… | — | withdrawn | Sep 26, 2014 | University of Southern California | PI left institution | Investigator |
| NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Feb 4, 2014 | Philogen S.p.A. | Lack of enrollment | Enrollment / accrual |
| NCT00003453 | Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow enrollment | Enrollment / accrual |
| NCT02261805 | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | Phase 1 / Phase 2 | terminated | Oct 10, 2014 | Georgetown University | Company terminated drug support | Sponsor / business decision |
| NCT01188486 | Pulmonary Interstitial Lymphography in Early Stage Lung Cancer | N/A | terminated | Aug 25, 2010 | Stanford University | Business decision | Sponsor / business decision |
| NCT00265200 | Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer | Phase 2 | terminated | Dec 14, 2005 | University of Louisville | funding discontinued by sponsor | Funding |
| NCT01237678 | A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell… | Phase 1 / Phase 2 | terminated | Nov 9, 2010 | ImmunoGen, Inc. | Study was stopped early due to lack of efficacy signal and safety concerns | Safety / toxicity |
| NCT02297087 | Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for… | N/A | terminated | Nov 21, 2014 | Western Regional Medical Center | PI no longer at site and he does | Other (stated, no rule matched) |
| NCT00003496 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell… | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and… | Phase 1 | withdrawn | Jul 13, 2016 | Vanderbilt-Ingram Cancer Center | Loss of funding support | Funding |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV…(THEN) | Phase 2 | withdrawn | Aug 23, 2016 | Fondation Hôpital Saint-Joseph | medical decision | Other (stated, no rule matched) |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | — | terminated | Mar 22, 2016 | Pathway Genomics | Patient accrual was slow due to exclusion of patients with prior cancers | Enrollment / accrual |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | Phase 2 | withdrawn | Apr 23, 2015 | John Villano | slow accrual | Enrollment / accrual |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT01575782 | Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung…(Chloroquine) | Phase 1 | terminated | Apr 11, 2012 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 26, 2020source: clinicaltrials